| Description |
Recombinant Human PLVAP Protein is expressed from HEK293 with His tag at the N-Terminus.It contains Tyr49-Gly442. |
| Purity |
> 95% as determined by Tris-Bis PAGE |
| Accession |
Q9BX97 |
| Target Symbol |
PLVAP |
| Species |
Human |
| Expression System |
HEK293 |
| Tag |
N-His |
| Expression Range |
Tyr49-Gly442 |
| Mol. Weight |
The protein has a predicted MW of 45.97 kDa. Due to glycosylation, the protein migrates to 50-70 kDa based on Tris-Bis PAGE result. |
| Form |
Lyophilized |
| Formulation |
Lyophilized from 0.22um filtered solution in PBS, 200mM L-arginine (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Endotoxin |
Less than 1EU per ug by the LAL method. |
| Storage |
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipping |
Shipped at ambient temperature. |
| Gene Background |
Plasmalemma vesicle-associated protein (PLVAP, also called PV-1) is the only protein that forms endothelial diaphragms. PLVAP expression is very low in the normal blood-retinal barrier; however, pathological factors such as high glucose and vascular endothelial growth factor (VEGF) induce its expression, leading to the exacerbation of cellular permeability. Because the new blood vessels are fragile and leaky, PLVAP could possibly be considered a therapeutic target against retinovascular diseases. |
